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Lung cancer accounts for 12% of all cancers and 
has the highest annual rate of mortality in men 
and women [1]. Almost 60% of patients at the 
moment of diagnosis are not eligible for radical 
treatment [2–5]. 
 Standard treatment options may include pallia-
tive external beam radiation therapy, in combina-
tion with chemotherapy or with chemotherapy and 
biological therapy, and any laser therapy or brachy-
therapy if needed [2, 5, 6].
Palliative radiotherapy may be used in different 
metastatic sites, osseous, cerebral, subcutaneous, 
nodal, or pulmonary to improve the quality of life 
and minimize symptoms [4]. Thoracic radiotherapy 
is a cornerstone in management of advanced stage 
III and IV lung cancer patients [7, 8] and bone ra-
diotherapy is a successful method to palliate pain 
and/or prevent morbidity [9, 10]. 
AbstrAct
background: Lung cancer is the most common cancer worldwide. It is estimated that 60% of patients with NscLc at time 
of diagnosis have advanced disease. The aim of this study was to identify factors that play a major role in the survival of lung 
cancer patients treated with palliative radiotherapy.
Materials and methods: We retrospectively reviewed data of 280 lung cancer patients treated with palliative radiotherapy 
from January 2013 to December 2017. a multivariate analysis using the proportional hazards model of cox was conducted. 
also, Kaplan Meier curves were used to describe the distribution of survival times of the patients. The level of significance 
was set at 0.05.
results: The mean age at diagnosis was 65.6 years. about 77.5% of patients were male and 22.5% were female. In our cohort 
> 95% had stage 4 lung cancer. Most cases were adenocarcinomas (72.5%) and ecOG-ps 0–1 (80.4%). Different sites were 
submitted to palliative treatment: 120 brain metastases, 96 bone metastases, 53 lung tumour, 8 lymph nodes and 3 lung 
metastases. Brain as first site of palliative radiotherapy (hr: 1.553, 95% cI: 1.167–2.067, p = 0.003) and ecOG-ps 2–3 compared 
with ecOG-ps 0–1 (hr: 2.253, 95% cI: 1.546–3.283, p ≤ 0.001) were associated with increased likelihood of lung cancer death. 
patients who received biological therapy had 70.7% (p ≤ 0.001) reduction in lung cancer death risk.
conclusion: Brain as the first metastatic site treated with radiotherapy and ecOG-ps 2–3 are associated with increased lung 
cancer death. Biological therapy was associated with decreased death risk.
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The purpose of this study was to identify factors 
that play a major role in the survival of lung cancer 
patients treated with palliative radiotherapy for the 
first time in our department. 
Materials and methods
This study is a retrospective analysis of patients 
from a single academic hospital (Centro Hospitalar 
Universitário de São João in Porto, Portugal). This 
study was approved by the institutional ethical re-
view board (reference number: 204/19). All lung 
cancer patients treated with first course of palliative 
radiotherapy between January 2013 and December 
2017 were included (n = 280). Electronic health 
records were collected in February 2019. Follow-up 
time was defined as the time between date of radio-
therapy and date of death or last clinical visit. Lung 
cancer specific survival was defined as the time 
from the date of first radiotherapy course to the 
date of death from lung cancer.
The Chi-square (χ2) test was used to compare the 
clinicopathological features among different sites 
of metastases. The distribution of the lung cancer 
specific survival was estimated by the Kaplan-Meier 
method. We performed the log-rank test to analyse 
variables for lung cancer specific survival, consid-
ering the following variables of interest: age (< 70 
years old vs. ≥ 70), ECOG-PS (0–1 vs. 2–3), smok-
ing, alcohol, gastro-intestinal disease, lung disease, 
cardiac disease, hypertension, diabetes mellitus, 
stage, pathology, palliative RT localization (brain 
vs other), surgery, chemotherapy, biological therapy 
and further course of radiotherapy. RT character-
istics including dose per fraction and number of 
fractions were used to quantify equivalent dose in 
2Gy per fraction (EQD2, alpha/beta = 10). 
We evaluated acute toxicity by Toxicity crite-
ria of the Radiation Therapy Oncology Group 
(RTOG) [11].
Cox proportional hazards regression modelling 
was used to assess the outcome of death caused 
by lung cancer, adjusted for significant clinical 
covariates. The covariates were the following: age 
(< 70 years old vs. ≥ 70), ECOG-PS (0–1 vs. 2–3), 
biological therapy, chemotherapy, palliative RT lo-
calization (brain vs other), gastro-intestinal disease, 
lung disease, cardiac disease, hypertension, diabe-
tes mellitus, smoker, alcohol and further course of 
radiotherapy. We presented graphically the curves 
of lung cancer specific survival. All analyses were 
performed using an IBM® SPSS® Statistics V25 and, 
for all, a level of significance α = 0.05 was noted.
results
In our department, between January 2013 and 
December 2017, we treated 280 lung cancer pa-
tients with the first course of palliative radiotherapy 
without previous irradiation. 
The most common irradiated metastatic sites 
were the brain (43%) and bone metastases (34%). 
Most patients were diagnosed at the stage IVA 
(p < 0.001) and predominant histology was ad-
enocarcinoma (p = 0.003) among different sites of 
metastases. 
Patients with lung tumour were more likely to re-
ceive pathological confirmation (p < 0.001), unlike 
brain and bone metastases. Further course of ra-
diotherapy was more frequent for bone metastases 
than other metastasis sites (p < 0.001). 
The clinical characteristics were summarized in 
Table 1. 
During the course of the disease, patients were 
submitted to other treatments, such as surgery, 
chemotherapy, biological therapy (immune check-
point inhibitors or tyrosine kinase inhibitors), il-
lustrated in Table 1. 
We irradiated different sites of bone metastases, 
as illustrated in Table 2. Most of them were verte-
bral metastases (n = 48, 50%) followed by pelvic 
metastases (n = 15, 15.6%). The radiotherapy goal 
was to control the pain (n = 93, 96.9%) and we ir-
radiated 3 spinal cord compressions. 
On palliative irradiation of the lung tumour, the 
main goal was to control pain (n = 30, 56.6%) fol-
lowed by growth control (n = 13, 24.5%). On irradi-
ation of the lymph nodes, most of them were on the 
mediastinum (n = 4) followed by the axilla (n = 3) 
and the main goal was growth control (n = 4, 50%). 
Total radiotherapy doses varied between 8 and 45 
Gy and all patients were treated with 3D conformal 
radiation therapy. Different radiotherapy schemes 
were performed according with symptomatology 
and localization. The most common dose fractiona-
tion for brain and bone metastases was 30 Gy in 10 
fractions and 40 Gy in 16 fractions on lymph nodes. 
Most of lung tumour and lung metastases were 
submitted to 45 Gy in 18 fractions and 40 Gy in 16 
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fractions. Treatment characteristics are detailed in 
Table 3.
In terms of EQD2 (a/b = 10), we presented the 
value in accordance with metastases localization. 
For lung tumour and lung metastases doses varied 
between 31.25 to 46.88 Gy and 41.67 Gy, respec-
tively. Dose to brain metastases varied between 
12.0 and 32.5 Gy and most of patients received 
30  Gy in 10 fractions (74.2%). The scheme most 
applied to bone metastases was 30 Gy in 10 frac-
tions (37.5%), dose range of 12.0 to 41.67 Gy. We 
treated 8 lymph nodes metastases with a dose 
range of 23.3 to 46.88 Gy.
Table 4 illustrates radiotherapy acute toxicity ac-
cording to the site of metastasis. With lung radio-
therapy the most common toxicities were grade 1 
RTOG. 
Brain radiotherapy revealed grade 1 RTOG in 
the skin (n = 10, 8.3%). In patients undergoing 
bone radiotherapy, revealed grade 1 RTOG in the 
skin (n = 4, 4.2%) and in patients whose radio-
therapy field included the lung, grade 1 RTOG in 
the lung was documented in 7 patients (1.3%).
The median follow-up time was 5 months 
(IQR = 11). The univariate analysis indicated that 
ECOG 0–1 vs. ECOG 2–3 (median 16.8 months 
(95% CI: 13.5–20.0) vs. 5.3 months (95% CI: 
3.5–37.2), p < 0.001), chemotherapy (median 15.3 
months (95% CI: 12.4–18.2) vs. 3.7 months (95% CI: 
table 2. Bone and lymph metastases and lung tumour characteristics treated with palliative radiotherapy
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0.7–6.7), p = 0.008) and biological therapy (median 
32.1 months (95% CI: 24.5–39.7) vs. 9.4 months 
(95% CI: 7.4–11.4), p < 0.001) were correlated with 
lung cancer specific survival. Patients treated with 
palliative brain radiotherapy revealed significant-
ly lower lung cancer specific survival when com-
pared to other sites (median 12.9 months (95% 
CI: 8.9–16.9) vs. 15.7 months (95% CI: 12.2–19.2), 
p = 0.031), illustrated in Table 5 and Figure 1.
Multivariate analysis revealed that brain as the 
first site of metastasis, ECOG 2–3 and biological 
therapy were independent prognostic factors for 
metastatic lung cancer survival. 
Patients treated with brain radiotherapy were as-
sociated with worst lung cancer specific survival 
(HR: 1.553, 95% CI: 1.167–2.067, p = 0.003), simi-
lar to ECOG 2–3 (HR: 2.253, 95% CI: 1.546–3.283, 
p < 0.001), whereas patients who had undergone 
biological therapy presented better lung can-
cer specific survival, 70.7% (HR: 0.293, 95% CI: 
0.197–0.436, p < 0.001) reduction in lung cancer 
death, as illustrated in Table 6 and Figure 1. 
Discussion
The present study explored the characteristics 
and outcomes of metastatic lung cancer patients 
undergoing first course of palliative radiotherapy, 
without previous irradiation.
The median survival rate reported, 5 months, 
resembles a large clinical trial [2, 3].
We treated 280 patients with palliative radio-
therapy and the brain was the most prevalent lo-
calization (n = 120) followed by the bone (n = 96). 
Metastatic sites patterns are globally in accordance 
with those stated in other studies. Previous stud-
ies have shown that the most common metastatic 
sites in lung cancer are the brain, bone, respira-
tory system, liver, and adrenal glands [12, 13]. 
Riihimaki et al (2014) studied 17.431 lung can-
cer patients diagnosed between 2002 and 2010 
and revealed population-based data on metastatic 
sites. Bone (39%) and respiratory system (22%) 
metastases were prevalent in adenocarcinoma, 
which is in accordance with the pathology dis-
tribution in our study, where adenocarcinoma 
was the most prevalent. For small cell cancer they 
found higher prevalence of nervous system (47%) 
and liver (35%) metastases [12]. Another study 
showed a total of 54,687 patients with metastatic 
lung cancer between 2010 and 2014. The most 
prevalent were multiple organ metastases (37.2%) 
followed by bone metastases (20%), lung metas-
tases (17.2%), brain metastases (15.2%) and liver 
metastases (10.4%) [14].
We applied different doses, in accordance with 
patient characteristics, treatment localization and 
department experience. Janssen et al. [15] reported 
in a retrospective analysis of 125 patients that in-
creasing equivalent dose in 2 Gy fractions (EQD2) 
led to significantly better survival outcomes. EQD2 
of 31–40, 41–46 and 47–52 Gy led to 6-month 
overall survival of 30, 38 and 57%, respectively, 
and 1-year overall survival of 11, 26 and 36%, re-
spectively. On multivariable analysis, EQD2 was 
significant. The doses of radiotherapy described by 
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Janseen et al. were higher compared with those 
used in our study. In addition, Frank et al. [16] 
investigated 159 patients with NSCLC and com-
pared 30 Gy/10 fractions, 25 Gy/five fractions, 15 
Gy/three fractions and 10 Gy/one fraction, find-
ing no statistically significant correlation between 
overall survival and radiotherapy regimes. It is dif-
ficult to directly compare this study with others 
finding a positive correlation between increased 
fractionation and overall survival, as the fraction-
ation schemes utilized in each study are variable 
with a large range in EQD2.
table 5. results of univariate analysis for lung cancer specific survival 
Lung cancer survival rate  
at 1 year (%), (months)
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An optimal radiotherapy regimen palliates 
symptom with minimal toxicity. In general, the 
published data regarding toxicity, reveals that treat-
ment was well tolerated [16–18].
In multivariate analysis (Tab. 6), this study re-
vealed that statistically significant factors with sur-
vival impact were ECOG 2–3 (p < 0.001), biological 
therapy (p < 0.001), and brain as first sites of me-
table 6. results of multivariate analysis for lung cancer specific survival. Multivariate analysis was performed that included 
clinically important variables and variables with statistical p < 0.05 by the univariate analysis
p HR
95% CI for HR
Lower Upper
age ≥ 70 y/o (ref: < 70 y/o) 0.995 0.999 0.733 1.362
ecOG-ps 2-3 (ref: ecOG-ps 0-1) < 0.001 2.253 1.546 3.283
Biological therapy (ref: no) < 0.001 0.293 0.197 0.436
chemotherapy (ref: no) 0.235 0.630 0.294 1.349
Brain metastases (ref: others) 0.003 1.553 1.167 2.067
Gastrointestinal disease (ref: no) 0.691 1.092 0.707 1.687
Lung disease (ref: no) 0.387 0.850 0.588 1.228
cardiac disease (ref: no) 0.620 0.905 0.612 1.340
hypertension (ref: no) 0.389 1.140 0.847 1.534
DM (ref: no) 0.960 0.990 0.662 1.480
smoker (ref: no) 0.830 1.039 0.732 1.476
alcohol (ref: no) 0.608 0.922 0.677 1.256
another course of radiotherapy (ref: no) 0.062 0.693 0.472 1.018
hr — hazard ratio; cI — confidence interval; DM — diabetes mellitus; ecOG-ps — eastern cooperative Oncology Group — performance status
Figure 1. Lung cancer specific survival curves in patients treated with palliative radiotherapy between 2013 and 2017 
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tastases (p = 0.003). Specifically, the risk of lung 
cancer death with brain metastases was 1.6 times 
greater than other sites and ECOG 2–3 patients 
had a risk of lung cancer death 2.3 times greater 
than ECOG 0–1. The finding that the performance 
status is significantly correlated with survival is 
in concordance with other studies [19, 20]. Li et 
al. (2019), performed a multivariate analysis that 
included gender, age at diagnosis, race, histology, 
tumour grade, tumour stage, surgery of metastases, 
using chemotherapy and radiotherapy and metas-
tases site. All of those were independent prognos-
tic factors for cancer specific survival. They used 
brain metastases as the reference and patients with 
isolated bone metastases had similar cancer-spe-
cific-survival. In this study, lung metastases repre-
sented better cause-specific survival. On the other 
hand, liver and multisite metastases were associated 
with worse cause-specific-survival [12, 14].
Riihimaki et al (2014) showed in their publica-
tions a five-month median survival after diagnosis 
for liver and bone metastases as the worst prog-
nosis [12]. The differences of our results may be 
explained by a lower number of patients. 
Most patients in our cohort received other treat-
ments, such as chemotherapy or biological therapy. 
In our analysis, those treatments were associated 
with a decrease in lung cancer death risk on univar-
iate analysis. Multivariate analysis revealed greater 
lung cancer specific survival in patients who had 
undergone biological therapy. Our study did not 
take into account the gene expression or check-
point inhibitors expression; however, the new tar-
get therapies and immunotherapy are changing the 
course of this disease, especially for patients having 
tumour presenting some gene mutation drivers, 
like EGFR (21, 22), ALK translocation [23, 24] and 
ROS arrangement [25, 26] or programmed death 
ligand 1 (PD-L1) expression [27, 28].
We should acknowledge that there are limita-
tions in our study. It is a retrospective study with 
heterogeneous metastatic disease patients and there 
was a lack of details about chemotherapy, biological 
therapy and gene expression which may cause bias. 
conclusion
In patients with distant metastases treated with 
palliative radiotherapy at our institution, those with 
brain metastases have the worse lung cancer spe-
cific survival as compared to other metastatic sites. 
Biological therapy was associated with decreased 
death risk and better survival.
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